Antiestrogenic agent-1
Antiestrogenic agent-1, an organophosphorus 13α-estrone derivative, is an antiestrogenic agent. Antiestrogenic agent-1 can disrupt estrogen signaling by inhibiting estrogen-mediated transcriptional activity. Antiestrogenic agent-1 can inhibit cancer cells proliferation, migration, invasion and induce G1-phase arrest. Antiestrogenic agent-1 mitigates estrogen-induced uterine growth in immature rats and inhibits tumor growth in a murine triple-negative breast cancer mice model. Antiestrogenic agent-1 can be used for the researches of cancer and endocrinology,such as breast cancer, oropharyngeal squamous cell carcinoma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C32H35O3P
- Molecular Weight:498.59
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
In Vitro
Antiestrogenic agent-1 (Compound EDPO) (0.4-60 μM; 24 h) inhibits estrogen-mediated transcriptional activity in T47D-KBluc cells with an IC50 of 10 μM[1].
Antiestrogenic agent-1 shows substantial
antiproliferative effect against T47D breast cancer cells and UPCI-SCC-131 oropharyngeal squamous cell carcinoma cells, with IC50 values of 7.2 μM and 5.3 μM[1].
Antiestrogenic agent-1 (1.75-7 μM; 12-72 h) induces time- and dose-dependent G1-phase cell cycle arrest in T47D cells[1].
Antiestrogenic agent-1 (2.5-5 μM (UPCI-SCC-131); 3.5-7 μM (T47D); 24-48 h) reduces migration of UPCI-SCC-131 and T47D cells in a time- and concentration-dependent manner[1].
Antiestrogenic agent-1 (3.5-7 μM; 48 h) decreases the invasive capacity of T47D cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:T47D (ERα+ human breast cancer cell line)
-
Concentration:1.75, 3.5 and 7 μM
-
Incubation Time:12, 24, 48, 72 h
-
Result:Induced substantial time- and dose-dependent G1-phase cell cycle arrest.
Increased G1 population and decreased S phase population at all time intervals, showed most pronounced arrest at 24 h.
-
Cell Line:UPCI-SCC-131 (human oropharyngeal squamous cell carcinoma cell line), T47D (ERα+ human breast cancer cell line)
-
Concentration:2.5 and 5 μM (UPCI-SCC-131); 3.5 and 7 μM (T47D)
-
Incubation Time:24, 48 h (UPCI-SCC-131); 24, 48 h (T47D)
-
Result:Significantly reduced cell migration in both cell lines in a time- and concentration-dependent manner.
Achieved significant effect at both concentrations at 24 h, and only at 5 μM at 48 h for UPCI-SCC-131.
Achieved significant effect at both concentrations at 24 and 48 h for T47D.
In Vivo
Antiestrogenic agent-1 (10-30 μg/g; i.p.; daily; 16 days) exerts significant dose-dependent antitumor activity against BALB/c mice with 4T1 triple-negative breast cancer[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (female, 21 days old, 35-47 g, 17β-estradiol-induced uterine growth)[1]
-
Dosage:60, 600 μg/g
-
Administration:S.c.; daily; 3 days
-
Result:Mitigated 17β-estradiol-induced uterine growth in a dose-dependent manner.
Showed no significant difference in inhibitory effects on uterine tissue growth compared to Fulvestrant (HY-13636) at the higher dose.
-
Animal Model:BALB/c mice (female, 8-10 weeks old, orthotopic 4T1 murine breast cancer)[1]
-
Dosage:10, 30 μg/g
-
Administration:I.p.; daily; 16 days
-
Result:Induced a significant and dose-dependent reduction in tumor growth throughout the 16-day treatment period.
Reduced tumor growth significantly from day 2 onwards at the higher dose.
- Dual Luciferin reporter gene assay
- Cell migration
- Research Protocol for Endocrine Diseases
- Patient-Derived Xenograft (PDX)
- Patient-Derived Orthotopic Xenograft (PDOX)
- Cell invasion
- Subcutaneous Cell-Line-Derived Xenograft
- Breast Cancer Modeling
- Orthotopic Cell-Line Xenograft
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
Molecular Weight 498.59
-
Formel C32H35O3P
-
SMILES
C[C@@]1([C@](C[C@H]2CP(C3=CC=CC=C3)(C4=CC=CC=C4)=O)([H])[C@]5([H])CCC6=C(C=CC(OC)=C6)[C@@]5([H])CC1)C2=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Antiestrogenic agent-1 Related Classifications
HY-181136 Related Classifications
Powered by Bioz